(6S)-N'-Propyl-4,5,6,7-Tetrahydro-1,3-Benzothiazole-2,6-Diamine Hydrate Dihydrochloride

(6S)-N′-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrate dihydrochloride — the compendial pramipexole dihydrochloride monohydrate reference standard — is supplied as a white to off-white crystalline powder with a nominal molecular formula C₁₀H₁₇N₃S·2HCl·H₂O and a relative molecular mass of 302.26 g·mol⁻¹. The material is certified against the current United States Pharmacopeia (USP) Pramipexole Dihydrochloride RS monograph and the equivalent European Pharmacopoeia (Ph. Eur.) standard, with batch-specific identity confirmed by Fourier-transform infrared spectroscopy (ATR-FTIR) against an in-house reference spectrum collected at 4 cm⁻¹ resolution over the range 4000–400 cm⁻¹. Potentiometric titration of chloride content with 0.1 N silver nitrate under USP <221> yields a stoichiometric ratio of 2.01 ± 0.05, confirming the dihydrochloride salt form. The monohydrate stoichiometry is verified by Karl Fischer coulometric titration (USP <921>, Method Ia) with a water content acceptance window of 4.5–5.5% (w/w); typical values for production-scale qualification lots fall within 4.8–5.2%, a range maintained through controlled crystallisation from aqueous ethanol followed by drying at 40°C under 25 mbar vacuum until loss on drying (USP <731>, 105°C for 3 h) stabilises below 0.3% beyond the hydrate water.

The product identity code PRM-2HCl·H₂O-RS is offered in amber Type I glass vials under argon overlay, with net contents of 100 mg or 200 mg. Each vial is sealed with bromobutyl rubber stoppers and aluminium flip-off caps; gas-chromatographic headspace analysis (USP <467>) confirms residual oxygen below 0.5% (v/v) post-sealing. The certificate of analysis supplied with every lot includes chromatographic purity by reversed-phase HPLC using a 250 mm × 4.6 mm octadecylsilane column (L1 packing, 5 µm) with UV detection at 264 nm, a mobile phase consisting of phosphate buffer (pH 3.0) and acetonitrile in gradient mode, and quantitation against the pramipexole dihydrochloride reference standard. The total impurity burden is controlled below 0.10% (area normalization), with the des-propyl amine impurity (CAS 104632-27-1) limited to a reporting threshold of 0.05% per ICH Q3A(R2) identification thresholds for a daily dose of 0.5 to 2.0 mg. Enantiomeric purity is determined by direct chiral HPLC on an amylose tris(3,5-dimethylphenylcarbamate) stationary phase (Chiralpak IA, 250 × 4.6 mm, 5 µm) with a mobile phase of n-hexane/ethanol/diethylamine 80:20:0.1 (v/v/v); the (R)-enantiomer is resolved with a minimum resolution of 3.0 from the (S)-peak and is routinely controlled at ≤0.1%.

What Distinguishes the Dihydrochloride Monohydrate from Anhydrous and Free-Base Forms?

The hydrate salt form dictates the material’s behaviour in both analytical and formulation contexts. The free base (pramipexole, CAS 104632-26-0) exhibits poor aqueous solubility — approximately 1.2 mg·mL⁻¹ in unbuffered water at 25°C — while the dihydrochloride monohydrate dissolves to >100 mg·mL⁻¹ under the same conditions, a property essential for the preparation of stock solutions for dissolution testing and for achieving content uniformity in low-dose tablet blends. The anhydrous dihydrochloride can form when the monohydrate is exposed to temperatures exceeding 65°C at relative humidity below 20%; such conversion alters the water content specification and shifts the specific rotation measured at 589 nm (sodium D-line) from the monohydrate range of +67° to +71° (c = 1, water, Ph. Eur. method 2.2.7) to a lower absolute value because of partial racemisation risk under forced drying. The loss of lattice water also increases the material’s hygroscopicity, leading to moisture sorption of up to 4% (w/w) within 4 h when exposed to 60% RH at 25°C, as measured by dynamic vapour sorption (DVS) with a step size of 10% RH and an equilibrium criterion of dm/dt ≤0.002%·min⁻¹. Consequently, the monohydrate is the only form accepted by the major pharmacopoeial monographs for reference standard and active pharmaceutical ingredient (API) use; the anhydrous salt and free base are classified as starting materials or intermediates in the synthetic pathway and are not interchangeable in validated analytical procedures.

The chiral integrity of the dihydrochloride monohydrate is monitored beyond simple enantiomeric ratio. Specific rotation measurement at 365 nm (mercury line) yields approximately +250° to +260° (c = 1, water), providing a more sensitive gauge of optical purity than the D-line reading; a deviation greater than ±2° from the lot mean triggers re-analysis by chiral HPLC. In manufacturing-scale crystallisation campaigns, seeded cooling from 65°C to 5°C in a water/ethanol (30:70 v/v) solvent system at a linear cooling rate of 0.1 K·min⁻¹ consistently delivers cGMP batches with 99.7% enantiomeric excess, as verified against a working standard calibrated with a 99.9% e.e. primary reference material traceable to the Ph. Eur. chemical reference substance.

Chiral HPLC Purity Verification at 264 nm

The compendial monographs (e.g., USP Pramipexole Dihydrochloride RS, Ph. Eur. monograph 2414) prescribe liquid-chromatographic identity and purity assessment, but practical experience in quality-control laboratories reveals that the column thermostating temperature is the single most influential variable in the chiral separation. When operated at ambient temperatures fluctuating between 20°C and 25°C, the retention time of the (S)-enantiomer can shift by up to 0.8 min on a 250 mm Chiralpak IA column, compromising the resolution relative to the des-propyl impurity. To maintain a resolution factor consistently above 3.0, the column compartment must be jacketed at 30°C ± 0.5°C with a circulator bath; a Waters Alliance e2695 module equipped with a column heater/chiller accessory is specified for this method in multiple FDA-registered contract laboratories. Detection at 264 nm captures the absorption maximum of the aminothiazole chromophore and avoids interference from the diethylamine modifier, which shows a rising baseline below 250 nm. The injection precision (repeatability) requirement of ≤0.5% RSD for the (S)-peak area, based on six replicate injections of a 0.1 mg·mL⁻¹ solution in mobile phase, is achievable only when the autosampler needle wash solvent is ethanol/water 50:50 with 0.1% diethylamine; incomplete needle flushing causes carryover of the (R)-enantiomer that inflates the apparent impurity content by 0.02–0.05%.

When the monograph requirement for specific rotation falls outside the acceptance range upon receipt of a new reference standard lot — a scenario occasionally encountered after long-distance air freight under uncontrolled humidity — pre-conditioning at 25°C/45% RH for 48 h in a desiccator containing saturated potassium carbonate solution is performed before re-testing. DVS profiles confirm that the monohydrate lattice is restored within 24 h under these conditions; mass spectrometry water-loss thermograms (TGA/DSC coupled to a Hiden HPR-20 mass spectrometer) show the evolution of water at an onset temperature of 52°C, matching the reference lot. Published data for this specific reconstitution procedure are limited, but internal qualification reports across four production-scale batches indicate that specific rotation returns to within 0.5° of the certified value after this humidity treatment.

Dissolution performance testing of immediate-release pramipexole tablets (typically containing 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg, or 1.5 mg pramipexole dihydrochloride monohydrate per unit) is executed using USP Apparatus 2 (paddles) at 50 rpm in 500 mL of degassed 0.1 N hydrochloric acid at 37°C. The reference standard lysed from each vial must be used to prepare a stock solution at a concentration of 0.1 mg·mL⁻¹ calculated as the anhydrous free base; failure to correct for the hydrate water and the dihydrochloride salt factor (1.19 for the monohydrate salt-to-base conversion) results in a systematic bias of approximately 19% low recovery in the dissolution assay. In multi-site release testing programmes, this conversion factor is frequently misapplied when analysts assume the standard is the anhydrous free base, leading to out-of-specification results for the Q=80% at 15 min acceptance criterion. The Certificate of Analysis therefore explicitly states the base equivalent factor (0.839) for each vial.

When Tablet Disintegration Time Exceeds 15 Minutes in Direct Compression Blends

Direct compression formulations of pramipexole dihydrochloride monohydrate present processing challenges that do not arise with the macrocrystalline free base. The hydrate salt particles exhibit a D₉₀ of 45 µm after jet-milling, and their high surface energy promotes agglomeration during blending with microcrystalline cellulose (Avicel PH-102) in a bin blender operated at 12 rpm. When the ambient relative humidity at the compression suite exceeds 55%, agglomerates absorb moisture, causing a loss of fracture strength in the tablets and a commensurate increase in disintegration time beyond the typical 8–12 min range. In one GMP manufacturing campaign monitored with a humidity logger placed inside a Fette 3090i rotary press (Fette Compacting GmbH) with 28-station tooling, a humidity excursion from 48% to 62% RH over a 4 h shift correlated with an upward drift in disintegration time from 10 min to 19 min (measured per Ph. Eur. 2.9.1 in water at 37°C using discs). The root cause was traced to partial deliquescence of the dihydrochloride salt at the particle surface, confirmed by environmental scanning electron microscopy showing liquid bridging between particles at 60% RH. The corrective action specified addition of 0.5% (w/w) colloidal silicon dioxide (Aerosil 200) pre-sheared with the API for 10 min in a high-shear mixer at 500 rpm prior to final blending; this reduced moisture sensitivity and returned disintegration time to 9–11 min under the same humidity conditions, with tablet hardness maintained at 40–50 N.

The incompatibility of pramipexole dihydrochloride with basic lubricants such as magnesium stearate in high-shear environments has additional implications for content uniformity. When the lubricant is added at 1.0% (w/w) and blended for more than 5 min, the amine-containing API forms a partial salt-exchange complex with magnesium ions that reduces the effective chloride content and slows dissolution; in a full factorial DOE executed on a 10 kg scale, the dissolution at 15 min dropped from 93% to 78% as the blending time was increased from 3 min to 8 min. The solution adopted in validated commercial processes is the use of sodium stearyl fumarate (PRUV, JRS Pharma) at 0.5% level, which provides equivalent ejection force reduction on an instrumented tablet press (Killian T200) without the disproportionate dissolution loss.

^a) Inhibition constants determined in CHO cells expressing human recombinant D_2L or D₃ receptors using [³H]spiperone as radioligand; data adapted from Millan et al. (2002) J Pharmacol Exp Ther 303:791 and Coldwell et al. (1999) Br J Pharmacol 127:1696. Values are means of ≥3 independent experiments.

The significantly higher D₃/D₂ affinity ratio of pramipexole compared to ropinirole or rotigotine underpins its pharmacological differentiation and also dictates the stringency of the chiral purity specification. In vitro functional assays at recombinant D₃ receptors indicate that the (R)-enantiomer possesses an intrinsic activity at least 30-fold lower than the (S)-form; however, even enantiomeric impurities at the 0.5% level have been shown to exert no detectable effect on [³⁵S]GTPγS binding in striatal membranes (Newman-Tancredi et al., 2002, Eur J Pharmacol 442:45). Nonetheless, the pharmacopoeial limit of ≤0.1% for the (R)-enantiomer is maintained not for safety-relevant receptor interaction but to ensure batch-to-batch consistency in chiral optical rotation measurements, which are part of pharmacopoeial identification tests that distinguish pramipexole from structurally related impurities such as the 4,5,6,7-tetrahydrobenzothiazole-2,6-diamine des-propyl precursor.

Stability of the dihydrochloride monohydrate reference standard in its original sealed vial under the recommended storage condition of +2°C to +8°C has been confirmed over 36 months through a bracketed ICH Q1A(R2) protocol. A long-term station at 5°C ± 3°C shows no significant trend in total impurities (≤0.06% at 36 months, versus an initial value of 0.03%), and chiral purity remains above 99.95% e.e. The accelerated condition at 40°C/75% RH over 6 months results in a water content increase to 6.2% due to moisture ingress past the bromobutyl stopper, accompanied by a rise in the des-propyl impurity to 0.12%; this finding establishes the operational boundary that vials opened for longer than 4 h in an uncontrolled laboratory atmosphere must be re-qualified for water content before use in quantitative analysis. HPLC analysis following exposure of the compound to 0.1 N sodium hydroxide at 80°C for 24 h in forced degradation studies reveals complete conversion to the free base and the generation of a late-eluting oxidative species (t_R 2.3 relative to pramipexole) that is absent from the acid and peroxide stress profiles; its structure, identified by LC-MS as the N-oxide derivative, is specifically monitored in the related substances test with an acceptance criterion of ≤0.05%.

In dissolution method transfer from the originator to a generic development laboratory, the observed discriminative power of paddle speed on pramipexole release from a water-soluble matrix is another operational detail where the hydrate salt’s behaviour differs from the free base. At 25 rpm, a 0.25 mg pramipexole dihydrochloride tablet releases 82% drug at 15 min in 0.1 N HCl, whereas the same formulation containing the free base under identical conditions releases only 55% because of the lower intrinsic dissolution rate governed by the Noyes-Whitney equation. The extensive sink conditions provided by the salt form’s high solubility (> 100 mg·mL⁻¹) collapse the diffusion layer driving force and render the dissolution profile insensitive to small variations in surfactant level, which is not the case for the free base, where addition of 0.2% sodium dodecyl sulfate is required to achieve >80% release. This salt-form characteristic is utilised in the Ph. Eur. dissolution test for pramipexole tablets, which specifies dissolution medium without surfactant.

Avoid combination of the dihydrochloride monohydrate powder with basic excipients such as dibasic calcium phosphate dihydrate in dry blends, as 2-week stability studies at 40°C/75% RH have shown an increase in the des-propyl amine impurity to 0.35%, attributed to base-catalysed cleavage of the N-propyl group. Similarly, its use in hot-melt extrusion is restricted: at processing temperatures above 130°C, thermogravimetric analysis-mass spectrometry (TGA-MS) detects evolution of HCl gas concomitant with hydrate water loss, indicating onset of salt disproportionation. This boundary limits its application in amorphous solid dispersion manufacture to solvent-based techniques such as spray drying with an inlet temperature not exceeding 110°C.